Oral GnRH receptor antagonist
Category: Page block
This category indicates a piece on a page. This is not content that will be used throughout the website. A page block is a piece of content on a certain page, and you can edit it via this category
Nolasiban
Infertility
Contact
ObsEva SA Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland +41 (0)22 552 3840 ObsEva USA, Inc. 71 Commercial…
Advancing Novel Therapeutics for Women’s Reproductive Health
ObsEva is advancing a pipeline of orally administered, clinical-stage innovative compounds to treat women’s reproductive health conditions.
Ebopiprant
Oral PGF2α
receptor antagonist
Linzagolix – Endometriosis
(OBE2109)
Oral GnRH receptor antagonist
Linzagolix – Uterine Fibroids
(OBE2109)
Oral GnRH
receptor antagonist
Nolasiban (OBE001)
Oral oxytocin
receptor antagonist
Ebopiprant—Preterm Labor
Commercial Rights Exclusive Worldwide rights licensed to Organon Condition Preterm labor
Linzagolix – Endometriosis
Milestones EDELWEISS 3:Phase 3 Post-Rx F/U data expected (Q2:22)Phase 3 Post-Rx F/U-extension data expected (Q4:22) Clinical Studies Currently recruiting Commercial…